Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BST02 in Locally Advanced Liver Cancer
NCT06526832Phase 1Recruiting
- Sponsor
- Biosyngen
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BST02 in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), sponsored by Biosyngen. Primary endpoints: Adverse Events and Severe Adverse Events, Maximum Tolerated Dose and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
BST02
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06526832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06526832.